Glycan target specialist Tacalyx GmbH has raised €14m in seed financing to develop its anti-TACA cancer therapies. The funding round was led by new investor Thuja Capital, with participation from existing investors including Boehringer Ingelheim Venture Fund, Kurma Partners, and the Max Planck Society. Tacalyx plans to use the additional funding to advance its pipeline of cancer compounds and develop two of its novel antibodies. The company uses customised synthetic antigens in combination with antibody generation technologies to target specific glycan structures on cancer cells.
📢 Breakthrough Cancer Therapies Secured with €14m Funding
Introduction:
Glycan target specialist Tacalyx GmbH has announced that it has raised €14 million in seed financing to advance its anti-TACA cancer therapies. This funding will be used to develop its discovery-stage and preclinical pipeline of anti-TACA cancer compounds.
Main points:
- Tacalyx GmbH has doubled its seed financing to €14 million to support the development of its anti-TACA cancer therapies.
- The funding round was led by new investor Thuja Capital, and included participation from existing investors such as Boehringer Ingelheim Venture Fund, Kurma Partners, and High-Tech Gründerfonds.
- Tacalyx targets specific glycan structures that are expressed during embryonic development and on cancer cells. These glycan structures play a role in the interaction between integrins and the extracellular matrix on the surface of cancer cells.
- The company’s lead candidate, TCX-101, is an antibody-drug conjugate that targets these glycan structures on cancer cells. Tacalyx plans to develop two of its novel antibodies into late preclinical stage and advance several earlier stage programs with the additional funding.
- Tacalyx uses customised synthetic antigens in combination with antibody generation technologies to develop its pipeline of seven programs targeting both known and novel glycan structures with high relevance for human malignancies.
Conclusion:
Tacalyx has raised €14 million in seed funding to advance its anti-TACA cancer therapies. With this additional funding, the company plans to develop two of its compounds into clinical candidates and advance others to the point where they are ready for preclinical development. Tacalyx’s technology holds promise for novel and more effective treatment options for cancers that are currently inadequately treatable.
